Amgen Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +30

Amgen stock faces a margin test ahead of November 3 results

Earnings report Financial outlook Guidance raised AI-generated analysis

πŸ“… Amgen is scheduled to release third-quarter results on Tuesday, November 3, after the U.S. market close.

πŸ’° The company expects higher operating expenses including a USD 100 million upfront payment tied to a business-development deal.

πŸ“‰ Management forecasts full-year non-GAAP operating margins will decrease from 48% in Q2 to a range of 45% to 46%.

πŸš€ Growth brands Repatha, Evenity, Tezspire, and Imdelltra drove revenue increases of 37%, 38%, 42%, and 115% respectively in the second quarter.

πŸ“‰ Legacy products Prolia and XGEVA faced significant headwinds with revenue declines of 32% and 34% due to biosimilar competition.

πŸ’Š Amgen is advancing its pipeline with nine global Phase 3 MariTide trials involving olpasiran and xaluritamig.

πŸ—οΈ Capital expenditure for the year is guided at approximately USD 2.6 billion to support manufacturing expansion and R&D.

πŸ“ˆ Analysts expect third-quarter normalized earnings per share of USD 5.7876 and revenue of USD 10.08 billion.

πŸ” Investors will focus on management's update regarding MariTide enrollment and manufacturing capacity during the earnings call.

Bullish Signals
  • Growth brands demonstrated strong momentum with Repatha revenue rising 37% to USD 953 million, Evenity increasing 38% to USD 714 million, Tezspire gaining 42% to USD 486 million, and Imdelltra climbing 115% as it expands into Europe and China.
  • Management raised its full-year revenue outlook to a range of USD 38.2 billion to USD 39.4 billion, indicating confidence in overall top-line growth despite margin compression.
  • The company successfully delivered non-GAAP earnings per share of USD 6.29 in the second quarter, beating the consensus estimate of USD 5.62 with revenue reaching USD 10.05 billion.
Risk Factors
  • Management expects full-year non-GAAP operating margins to decline from 48% in the second quarter to a range of 45% to 46% due to higher spending and biosimilar pressure.
  • Legacy products Prolia and XGEVA faced substantial revenue declines of 32% and 34% respectively, driven by intense competition from biosimilars.
  • The company faces a planned increase in operating expenses including a USD 100 million upfront charge for a business-development deal recorded in R&D.
  • Analysts expect third-quarter normalized earnings per share of USD 5.7876, which is below the second-quarter result of USD 6.29, highlighting a sequential earnings decline.
Full Analysis
Amgen is preparing to release its third-quarter financial results on November 3, following the U.S. market close. The company faces a significant margin test as it anticipates higher operating expenses, specifically including a USD 100 million upfront charge related to a business-development deal recorded in research and development. Management has raised its full-year revenue outlook to between USD 38.2 billion and USD 39.4 billion, with non-GAAP earnings per share guidance adjusted to USD 22.30 to USD 23.50. However, the company expects its full-year non-GAAP operating margin to moderate from the second-quarter level of 48% to a range of 45% to 46% of product sales. Commercial performance remains critical as growth brands attempt to offset declining revenue from legacy products. While newer therapies like Repatha, Evenity, Tezspire, and Imdelltra showed strong double-digit or triple-digit revenue increases, established drugs Prolia and XGEVA suffered significant revenue declines of 32% and 34% respectively due to biosimilar competition. Amgen is also investing heavily in its pipeline, with ongoing Phase 3 MariTide trials and capital expenditure guided at approximately USD 2.6 billion. Investors will closely monitor the November 3 report for updates on MariTide enrollment, manufacturing expansion plans, and whether the company can successfully absorb increased spending while maintaining profitability.